- WHO: Latest 2024-2025 Influenza Vaccine Strain Recommendations
- 5-Year Diabetes Remission: Lancet Study Shows High Success with Weight Loss
- WHO: Slimming Pills Can’t Solve Global Obesity Problem for One Billion People
- Why Do Humans Not Have Tails?
- Chromosomal Abnormalities Found in North Korean Defectors Near Nuclear Test Site
- Cholera Vaccine Stockpile Depleted: 16 Countries in Crisis
How much do you know about alveolar soft tissue sarcoma?
How much do you know about alveolar soft tissue sarcoma? Alveolar soft tissue sarcoma is a rare soft tissue tumor. The source of the tissue is unknown. It is named for its unique acinar structure under the microscope.
Alveolar soft tissue sarcoma is a rare soft tissue tumor. The source of the tissue is unknown. It is named for its unique acinar structure under the microscope. It is more common in people aged 15-50, and it is more common in adolescent women.
Adult patients most often occur in the limbs, especially the deep tissues of the thighs. The most common parts of children and infants are the head and neck, especially the eyes and tongue. The clinical manifestation is a slow-growing deep soft tissue mass, which is often long and painless. Orbital lesions are most common as exophthalmos and swelling of the eyelids.
Alveolar soft tissue sarcoma is not highly malignant, and the tumor grows slowly. However, the blood supply is extremely rich, and the pathological examination shows thick tumor blood vessels, so blood metastasis is very easy to occur. The lung is the most common metastasis organ, but even if lung metastasis occurs, the prognosis is still good.
Imaging examinations have no specific manifestations except for tumors with high blood supply. Commonly used examinations include CT, MRI, and immunological examinations. The final diagnosis depends on tissue biopsy.
For limited-stage acinar soft tissue sarcoma, extended resection or radical resection is the only effective treatment to completely remove the tumor. The tumor is not sensitive to chemotherapy and radiotherapy, and the curative effect is uncertain, so regular follow-up visits must be made after surgery.
For inoperable patients with recurrence and metastasis, targeted drugs are the best choice. The currently marketed drugs pazopanib, apatinib and anlotinib all have certain effects.
(source:internet, reference only)